IceCure Medical Regains Nasdaq Compliance Following Reverse Stock Split
ICCM has more than doubled off its 52-week low of $2.12 on elevated volume (4.3× avg).
Summary
IceCure Medical has officially regained compliance with Nasdaq's minimum bid price requirement, receiving notice on June 18th. This positive development follows the 1-for-30 reverse stock split that became effective on June 4th, which was implemented to address the prior non-compliance. The company's shares maintained a bid price above $1.00 for 10 consecutive business days, successfully resolving the delisting threat. This removes a significant risk factor and ensures the company's continued listing on Nasdaq.
At the time of this announcement, ICCM was trading at $8.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $26.1M. The 52-week trading range was $2.12 to $42.00. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.